Hanchen Xu

Hanchen Xu

Auto-generated profile, based on publicly available information

Hanchen Xu

Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YLYunhua Liu
Yunhua Liu
HXHanchen Xu
Hanchen Xu
KJKevin Van der Jeught
Kevin Van der Jeught
YLYujing Li
Yujing Li
SLSheng Liu
Sheng Liu
XLXiongbin Lu
Xiongbin Lu
A synthetic lethality–based strategy has been developed to identify therapeutic targets in cancer harboring tumor-suppressor gene mutations, as exemplified by the effectiveness of poly ADP-ribose polymerase (PARP) inhibitors in BRCA1/2-mutated tumors. However, many synthetic lethal interactors are less reliable due to the fact that such genes usually do not perform fundamental or indispensable functions in the cell. Here, we developed an approach to identifying the “essential lethality” arising from these mutated/deleted essential genes, which are largely tolerated in cancer cells due to genetic redundancy. We uncovered the cohesion subunit SA1 as a putative synthetic-essential target in cancers carrying inactivating mutations of its paralog, SA2. In SA2-deficient Ewing sarcoma and bladder cancer, further depletion of SA1 profoundly and specifically suppressed cancer cell proliferation, survival, and tumorigenic potential. Mechanistically, inhibition of SA1 in the SA2-mutated cells led to premature chromatid separation, dramatic extension of mitotic duration, and consequently, lethal failure of cell division. More importantly, depletion of SA1 rendered those SA2-mutated cells more susceptible to DNA damage, especially double-strand breaks (DSBs), due to reduced functionality of DNA repair. Furthermore, inhibition of SA1 sensitized the SA2-deficient cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with SA2-deficient tumors.

5 March 2026 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YLYunhua Liu
Yunhua Liu
HXHanchen Xu
Hanchen Xu
KJKevin Van der Jeught
Kevin Van der Jeught
YLYujing Li
Yujing Li
SLSheng Liu
Sheng Liu
XLXiongbin Lu
Xiongbin Lu

25 November 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YLYunhua Liu
Yunhua Liu
HXHanchen Xu
Hanchen Xu
KJKevin Van der Jeught
Kevin Van der Jeught
YLYujing Li
Yujing Li
SLSheng Liu
Sheng Liu
XLXiongbin Lu
Xiongbin Lu
Park jointly notified the JCI of data falsification in Supplemental Figure 8A and Supplemental Figure 9E and misconduct findings against Xiongbin Lu and Yunhua Liu. In accordance with the investigation committee's recommendation, the JCI is retracting this article.